Conditions: Acute Lymphoid Leukemia Acute Myeloid Leukemia Anemia, Refractory, With Excess of Blasts Solid Tumors
Keywords: Acute Lymphoid Leukemia Myelodysplastic Syndrome Acute Myeloid Leukemia Solid Tumors Anemia, Refractory, with Excess of Blasts Antibodies, Monoclonal Antibody-Drug Conjugate Antigens, CD30 Drug Therapy Hematologic Diseases Immunotherapy Monomethyl Auristatin E
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 84
Healthy volunteers: no

Brief summary:
This is an open-label, multicenter, phase 2 clinical trial to evaluate the antitumor activity of brentuximab vedotin as a single agent in patients with CD30-positive nonlymphomatous malignancies.

Detailed description:

Arms:
arm 1: Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion arm 2: Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion arm 3: Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion

Interventions: intervention 1: brentuximab vedotin intervention 2: brentuximab vedotin intervention 3: brentuximab vedotin
Intervention descriptions: intervention 1: 1.8 mg/kg every 3 weeks by intravenous (IV) infusion intervention 2: 2.4 mg/kg every 3 weeks by intravenous (IV) infusion intervention 3: 1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion

Protocol document: